Neoantigen vaccine studies illustrate AI’s role in antigen prioritization, as seen in melanoma and NSCLC, where personalized immunotherapy combined with PD-1 blockade achieved promising efficacy [94]. This evidence concerns the gene SNCA and non-small cell lung carcinoma.